Diasome operates as a clinical-stage biopharmaceutical company that focuses on hepatocyte cell targeting to treat metabolic diseases. The company's main offerings include therapies that restore hepatocyte metabolism, addressing common metabolic disorders such as diabetes, obesity, and dyslipidemia. These therapies leverage the natural regulatory functions of hepatocytes. It was founded in 2004 and is based in Cleveland, Ohio.
Research containing Diasome
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Diasome in 1 CB Insights research brief, most recently on Oct 28, 2022.
Latest Diasome News
Dec 8, 2023
News provided by Diasome Secures Series C Funding with Eli Lilly Participation CLEVELAND, OH, USA, December 7, 2023 / EINPresswire.com / -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform to develop innovative therapies for diabetes, obesity, and other metabolic disorders, has announced the first closing of its Series C financing today. This funding round, led by current investors, also includes participation from Eli Lilly and Company. "We are gratified by the confidence shown in our work by the investors involved in this new funding," said Robert Geho, CEO of Diasome Pharmaceuticals. "This financing supports our ongoing clinical research and advancement of transformative treatments for people living with diabetes and other metabolic disorders." Diasome is preparing to initiate its OPTI-2 trial, a Phase 2b, double-blinded, randomized controlled trial in people with type 1 diabetes. The OPTI-2 trial will investigate the effect of Diasome's HDV™ Insulin compared to standard of care insulin therapy on blood glucose control and hypoglycemia prevention over a six-month treatment period. Diasome's pipeline features multiple innovative assets, including a low-dose oral incretin delivery system that explores the benefits of balanced hepatic and peripheral targeting. Additionally, the pipeline includes a novel hepatocyte-targeted drug strategy aimed at modulating a key underlying mechanism of type 2 diabetes. About Diasome Pharmaceuticals, Inc.: Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasome's Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocyte's natural regulatory functions. For additional details about Diasome Pharmaceuticals, Inc., please visit www.diasome.com Kent Manson
Diasome Frequently Asked Questions (FAQ)
When was Diasome founded?
Diasome was founded in 2004.
Where is Diasome's headquarters?
Diasome's headquarters is located at 10000 Cedar Avenue, Cleveland.
What is Diasome's latest funding round?
Diasome's latest funding round is Series C - IV.
How much did Diasome raise?
Diasome raised a total of $89.79M.
Who are the investors of Diasome?
Investors of Diasome include Eli Lilly and Company, Flare Capital Partners, Black Beret Life Sciences, McDonald Partners, Medicxi Ventures and 6 more.
Who are Diasome's competitors?
Competitors of Diasome include Adastra Pharmaceuticals, Intarcia Therapeutics, Amylin Pharmaceuticals, Tioga Pharmaceuticals, ISTA Pharmaceuticals and 7 more.
Compare Diasome to Competitors
Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.
Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company with a primary focus on oncology. The company is dedicated to developing innovative treatments for aggressive forms of cancer. Its primary customer base is within the healthcare industry, specifically those dealing with oncology. Adastra Pharmaceuticals was formerly known as Tragara Pharmaceuticals. It was founded in 2005 and is based in Princeton, New Jersey.
Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.
Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.